BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

475 related articles for article (PubMed ID: 29343651)

  • 1. Determining patient selection tool and response predictor for outpatient 30 mCi radioiodine ablation dose in non-metastatic differentiated thyroid carcinoma: a Japanese perspective.
    Higuchi T; Achmad A; Binh DD; Bhattarai A; Tsushima Y
    Endocr J; 2018 Mar; 65(3):345-357. PubMed ID: 29343651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Importance of postoperative stimulated thyroglobulin level at the time of 131I ablation therapy for differentiated thyroid cancer.
    Hasbek Z; Turgut B; Kilicli F; Altuntas EE; Yucel B
    Asian Pac J Cancer Prev; 2014; 15(6):2523-7. PubMed ID: 24761858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparable Ablation Efficiency of 30 and 100 mCi of I-131 for Low to Intermediate Risk Thyroid Cancers Using Triple Negative Criteria.
    Fatima N; Zaman MU; Zaman A; Zaman U; Tahseen R
    Asian Pac J Cancer Prev; 2016; 17(3):1115-8. PubMed ID: 27039734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-dose radioiodine therapy for patients with intermediate- to high-risk differentiated thyroid cancer.
    Abe K; Ishizaki U; Ono T; Horiuchi K; Kanaya K; Sakai S; Okamoto T
    Ann Nucl Med; 2020 Feb; 34(2):144-151. PubMed ID: 31834567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of Low-dose and High-dose Radioactive Iodine Ablation With rhTSH in Korean Patients With Differentiated Thyroid Carcinoma: The First Report in Nonwestern Countries.
    Joung JY; Choi JH; Cho YY; Kim NK; Sohn SY; Kim SW; Chung JH
    Am J Clin Oncol; 2016 Aug; 39(4):374-8. PubMed ID: 24732812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transient early increase in thyroglobulin levels post-radioiodine ablation in patients with differentiated thyroid cancer.
    Stevic I; Dembinski TC; Pathak KA; Leslie WD
    Clin Biochem; 2015 Jul; 48(10-11):658-61. PubMed ID: 25895485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outpatient ablation treatment with two doses of 30 mCi of radioactive iodine for non-low-risk papillary thyroid cancer.
    Uno A; Takeda H; Mori M; Yamamoto Y; Takenaka Y; Enomoto K; Takeda N
    J Med Invest; 2023; 70(1.2):17-21. PubMed ID: 37164716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Re-ablation I-131 activity does not predict treatment success in low- and intermediate-risk patients with differentiated thyroid carcinoma.
    Prpic M; Kruljac I; Kust D; Kirigin LS; Jukic T; Dabelic N; Bolanca A; Kusic Z
    Endocrine; 2016 Jun; 52(3):602-8. PubMed ID: 26732041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ongoing risk stratification for differentiated thyroid cancer (DTC) - stimulated serum thyroglobulin (Tg) before radioiodine (RAI) ablation, the most potent risk factor of cancer recurrence in M0 patients.
    Krajewska J; Jarząb M; Czarniecka A; Roskosz J; Kukulska A; Handkiewicz-Junak D; Puch Z; Wygoda Z; Paliczka-Cieślik E; Kropińska A; Gubała E; Jurecka-Lubieniecka B; Jarząb B
    Endokrynol Pol; 2016; 67(1):2-11. PubMed ID: 26884109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lithium as an adjuvant in the postoperative ablation of remnant tissue in low-risk thyroid carcinoma.
    Yamazaki CA; Padovani RP; Biscolla RP; Ikejiri ES; Marchetti RR; Castiglioni ML; Matsumura LK; Maciel RM; Furlanetto RP
    Thyroid; 2012 Oct; 22(10):1002-6. PubMed ID: 22953991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum thyroglobulin level after radioiodine therapy (Day 3) to predict successful ablation of thyroid remnant in postoperative thyroid cancer.
    Kim YI; Im HJ; Paeng JC; Cheon GJ; Kang KW; Lee DS; Joon Park D; Park YJ; Chung JK
    Ann Nucl Med; 2015 Feb; 29(2):184-9. PubMed ID: 25404419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison between the different doses of radioactive iodine ablation prescribed in patients with intermediate-to-high-risk differentiated thyroid cancer.
    Iizuka Y; Katagiri T; Ogura K; Mizowaki T
    Ann Nucl Med; 2019 Jul; 33(7):495-501. PubMed ID: 30955202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thyroglobulin measurement before rhTSH-aided 131I ablation in detecting metastases from differentiated thyroid carcinoma.
    Giovanella L; Ceriani L; Suriano S; Ghelfo A; Maffioli M
    Clin Endocrinol (Oxf); 2008 Oct; 69(4):659-63. PubMed ID: 18363882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Patients treated for differentiated thyroid cancer with negative 131I whole-body scans and elevated thyroglobulin levels: a possible course].
    Gutiérrez Cardo AL; Rodríguez Rodríguez JR; Borrego Dorado I; Navarro González E; Tirado Hospital JL; Vázquez Albertino R
    Rev Esp Med Nucl; 2007; 26(3):138-45. PubMed ID: 17524307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation.
    Barbaro D; Boni G; Meucci G; Simi U; Lapi P; Orsini P; Pasquini C; Piazza F; Caciagli M; Mariani G
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4110-5. PubMed ID: 12970272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 30mCi radioactive iodine achieving comparative excellent response in intermediate/high-risk nonmetastatic papillary thyroid cancer: a propensity score matching study.
    Zhang Y; Wang C; Zhang X; Li H; Li X; Lin Y
    Endocrine; 2018 Dec; 62(3):655-662. PubMed ID: 30145748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decreasing the dose of radioiodine for remnant ablation does not increase structural recurrence rates in papillary thyroid carcinoma.
    Kruijff S; Aniss AM; Chen P; Sidhu SB; Delbridge LW; Robinson B; Clifton-Bligh RJ; Roach P; Gill AJ; Learoyd D; Sywak MS
    Surgery; 2013 Dec; 154(6):1337-44; discussion 1344-5. PubMed ID: 24383104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unexpected radioactive iodine accumulation on whole-body scan after I-131 ablation therapy for differentiated thyroid cancer.
    Iwano S; Ito S; Kamiya S; Ito R; Kato K; Naganawa S
    Nagoya J Med Sci; 2020 May; 82(2):205-215. PubMed ID: 32581401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term course and predictive factors of elevated serum thyroglobulin and negative diagnostic radioiodine whole body scan in differentiated thyroid cancer.
    Alzahrani AS; Mohamed G; Al Shammary A; Aldasouqi S; Abdal Salam S; Shoukri M
    J Endocrinol Invest; 2005 Jun; 28(6):540-6. PubMed ID: 16117196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized clinical trial comparing 50mCi and 100mCi of iodine-131 for ablation of differentiated thyroid cancers.
    Zaman Mu; Toor R; Kamal S; Maqbool M; Habib S; Niaz K
    J Pak Med Assoc; 2006 Aug; 56(8):353-6. PubMed ID: 16967785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.